Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12637703 | 0.94 | HSP90AA1 (0.40) | ALDH1A1HPGDLMNAATMHSP90AA1 | |
| SCHEMBL419118 | 0.93 | ALDH1A1 (0.41) | ALDH1A1HPGDLMNAATMHSP90AA1 | |
| SCHEMBL12185616 | 0.87 | ALDH1A1 (0.40) | ALDH1A1HPGDLMNAATMHSP90AA1 | |
| SCHEMBL420101 | 0.84 | HSP90AA1 (0.42) | ALDH1A1HPGDLMNAATMHSP90AA1 | |
| SCHEMBL12908775 | 0.81 | GAA (0.34) | HPGDLMNAHSP90AA1KDM4EGAA | |
| SCHEMBL10344975 | 0.81 | ALDH1A1 (0.43) | ALDH1A1HPGDLMNAATMHSP90AA1 | |
| SCHEMBL16021996 | 0.79 | KDM4E (0.49) | ALDH1A1HPGDLMNAATMHSP90AA1 | |
| SCHEMBL419131 | 0.79 | HSP90AA1 (0.41) | ALDH1A1HPGDLMNAATMHSP90AA1 | |
| SCHEMBL421158 | 0.78 | HSP90AA1 (0.42) | ALDH1A1HPGDLMNAATMHSP90AA1 | |
| SCHEMBL8930907 | 0.78 | HSP90AA1 (0.43) | ALDH1A1HPGDLMNAATMHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130156755-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156755-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156755-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 1176/4885HPGD 956/4885LMNA 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.